世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000028539

精密癌診断検査市場レポート2021−2031

Visiongain

Precision Cancer Diagnostic Test Market Report 2021-2031

発刊日 2020/11/12

言語英語

体裁PDF/449ページ

「PDF」版449ページ

0000028539

精密癌診断検査市場レポート2021−2031
Precision Cancer Diagnostic Test Market Report 2021-2031

3,999 GBP

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数5人)をご検討ください。
※詳しくはお問い合わせください。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

カテゴリー別予測(癌イメージング、癌の分子検査、腫瘍マーカー免疫検定法、POC大腸がん検査)、癌イメージング検査別(CT、MRI、デジタル&アナログマンモグラフィー、PET、デジタル乳房トモシンセシス、乳房の分子検査)、癌の分子検査別(血液を用いた癌の分子検査、HPVジェノタイピング、循環腫瘍細胞(CTC)検査、次世代シーケンシング検査)、エンドユーザー(病院、クリニック、研究機関)、地域別および主要国市場分析、プラス、癌精密診断検査の主要企業、COVID-19回復シナリオ

精密癌診断検査−動向、研究開発の進歩、売上予測
精密癌診断検査市場はどこへ向かっているのでしょうか。Visiongainのレポートはデータ、動向、市場機会、事業の将来見通しについて分析、評価を行い、2030年までの収益の流れを明らかにします。

トップの座を維持するために
449ページのレポートに271の表、267の図とグラフを掲載。このレポートは世界市場全体と地域別の各レベルにおける売上を予測することが可能です。財務データ、動向、事業機会、売上予測を示します。COVID-19がそれぞれの業種にどのような影響を与えるのかについてデータの分析と貴重な見識が得られます。

レポート詳細

目次

1 Report Overview
1.1 Scope of the Report
1.2 Why You Should Buy This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.6.1 Primary Research
1.6.2 Secondary Research
1.7 Market Evaluation & Forecasting Methodology
1.8 COIVD-19 Impact Recovery Pattern Analysis
1.8.1 V-Shaped Recovery
1.8.2 U-Shaped Recovery
1.8.3 W-Shaped Recovery
1.8.4 L-Shaped Recovery
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain

2 Executive Summary

3 Cancer Diagnostics Overview
3.1 Diagnostics Overview
3.2 Arrays and Microfluidics (LOAC) Technologies
3.2.1 DNA Microarrays
3.2.2 Protein Microarrays
3.2.3 Microfluidics
3.3 Multiplex Conventional Technologies
3.4 Next Generation Sequencing Technology
3.5 Polymerase Chain Reaction (PCR) Technology
3.6 Liquid Biopsy Technologies
3.6.1 Cancer Genomics
3.7 Circulating Tumor Cell Technologies
3.8 CTC Workflow
3.9 Cell Isolation Technologies
3.9.1 The main industry advocate of cell adhesion is Menarini-Silicon Biosystems
3.10 CTC Sample Preparation Technologies
3.11 CTC Downstream Analysis Technologies
3.11.1 Comparison of Liquid Biopsy with Conventional Biopsy
3.12 Cancer Testing
3.13 Avatar-Driven Diagnostic Approaches

4 Market Drivers, Opportunities, and Challenges
4.1 Global Market Drivers
4.1.1 Increasing Global Spending On Oncology
4.1.2 Are significant new product launches propelling the market growth?
4.1.3 How Increased Cancer Patient Access and Value is Impacting Cancer Diagnostics Market?
4.2 What are the Opportunities in the Global Market?
4.2.1 How Modern Technologies will Drive growth for precision cancer diagnostic test market?
4.2.2 Cancer Medicine Will Be Highly Personalized
4.2.3 Innovations in Diagnostic Methods and Technology
4.3 What Are the Challenges in the Global Market?
4.3.1 Promising Diagnostic Tests Ultimately Fail Because Of Inadequate Performance In Real-World
4.3.2 Rigorous Evaluation Of New Tests Has Been A Challenge
4.3.3 Utilization Challenges for Precision Cancer Diagnostic tests
4.3.4 The Cost Associated With Testing For Genomic Alterations And Subsequent Targeted Therapy, Poses Implementation Challenge

5 Global Precision Cancer Diagnostic Test Market Outlook
5.1 Market Analysis by Value (COVID Impact Analysis)
5.1.1 COVID-19 V-Shaped Recovery Analysis
5.1.2 COVID-19 W-Shaped Recovery Analysis
5.1.3 COVID-19 U-Shaped Recovery Analysis
5.1.4 COVID-19 L-Shaped Recovery Analysis
5.1.5 Global market is expected to grow at a CAGR of 9.8% during the forecast period 2021-2031
5.2 Regional Market Analysis (COVID-19 Impact Analysis)
5.2.1 COVID-19 V-Shaped Recovery Analysis
5.2.2 COVID-19 W-Shaped Recovery Analysis
5.2.3 COVID-19 U-Shaped Recovery Analysis
5.2.4 COVID-19 L-Shaped Recovery Analysis
5.2.5 North America is projected to Lead the Global Market During Forecast Period
5.3 Global Market Analysis by Category (COVID-19 Impact Analysis)
5.3.1 COVID-19 V-Shaped Recovery Analysis
5.3.2 COVID-19 W-Shaped Recovery Analysis
5.3.3 COVID-19 U-Shaped Recovery Analysis
5.3.4 COVID-19 L-Shaped Recovery Analysis
5.3.5 Cancer Imaging market is projected to grow at a CAGR of 9.7% and Lead the Market
5.4 Global Market Analysis by Cancer Imaging Test Type (COVID-19 Impact Analysis)
5.4.1 COVID-19 V-Shaped Recovery Analysis
5.4.2 COVID-19 W-Shaped Recovery Analysis
5.4.3 COVID-19 U-Shaped Recovery Analysis
5.4.4 COVID-19 L-Shaped Recovery Analysis
5.4.5 Magnetic Resonance Imaging Segment is Projected to Grow at the Fastest Rate
5.5 Global Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
5.5.1 COVID-19 V-Shaped Recovery Analysis
5.5.2 COVID-19 W-Shaped Recovery Analysis
5.5.3 COVID-19 U-Shaped Recovery Analysis
5.5.4 COVID-19 L-Shaped Recovery Analysis
5.5.5 HPV Genotyping Segment is Projected to be the Fastest Growing Segment in the Market
5.6 Global Market Analysis by End-User (COVID-19 Impact Analysis)
5.6.1 COVID-19 V-Shaped Recovery Analysis
5.6.2 COVID-19 W-Shaped Recovery Analysis
5.6.3 COVID-19 U-Shaped Recovery Analysis
5.6.4 COVID-19 L-Shaped Recovery Analysis
5.6.5 Hospitals Emerged as the Major User and is Projected to Maintain the Dominance

6 North America Precision Cancer Diagnostic Test Market Outlook
6.1 North America Market Analysis by Value (COVID-19 Impact Analysis)
6.2 North America Market Analysis by Country (COVID-19 Impact Analysis)
6.3 US Market Analysis
6.3.1 US Cancer Snapshot 2019
6.3.2 US Market Analysis by Value (COVID-19 Impact Analysis)
6.3.3 In 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States
6.4 Canada Market Analysis
6.4.1 Canada Cancer Snapshot 2019
6.4.2 Canada Market Analysis by Value (COVID-19 Impact Analysis)
6.4.3 It is estimated that in 2020, 115,800 Canadian men will be diagnosed with cancer
6.5 North America Market Analysis by Category (COVID-19 Impact Analysis)
6.6 North America Market Analysis by Cancer Imaging Test Type (COVID-19 Impact Analysis)
6.7 North America Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
6.8 North America Market Analysis by End-User (COVID-19 Impact Analysis)

7 Europe Precision Cancer Diagnostic Test Market Outlook
7.1 Europe Market Analysis by Value (COVID-19 Impact Analysis)
7.2 Europe Market Analysis by Country (COVID-19 Impact Analysis)
7.3 Russia Market Analysis
7.3.1 Russia Cancer Snapshot 2019
7.3.2 Russia Market Analysis by Value (COVID-19 Impact Analysis)
7.3.3. In Russia, the overall risk of dying from cancer is about 60%,
7.4 Germany Market Analysis
7.4.1 Germany Cancer Snapshot 2019
7.4.2 Germany Market Analysis by Value (COVID-19 Impact Analysis)
7.4.3 By 2030, prostate cancer will be the most common malignancy, surpassing breast cancer
7.5 UK Market Analysis
7.5.1 UK Cancer Snapshot 2019
7.5.2 UK Market Analysis by Value (COVID-19 Impact Analysis)
7.5.3 By 2035, the number of new cancer cases is projected to rise to over half a million a year
7.6 France Market Analysis
7.6.1 France Cancer Snapshot 2019
7.6.2 France Market Analysis by Value (COVID-19 Impact Analysis)
7.6.3 One in two men and one in three women will be diagnosed with cancer
7.7 Italy Market Analysis
7.7.1 Italy Cancer Snapshot 2019
7.7.2 Italy Market Analysis by Value (COVID-19 Impact Analysis)
7.7.3 In Italy, in 2018, over 369,000 new cases of cancer were diagnosed
7.8 Rest of Europe Market Analysis by Value (COVID-19 Impact Analysis)
7.9 Europe Market Analysis by Category (COVID-19 Impact Analysis)
7.10 Europe Market Analysis by Cancer Imaging Test Type (COVID-19 Impact Analysis)
7.11 Europe Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
7.12 Europe Market Analysis by End-User (COVID-19 Impact Analysis)

8 Asia-Pacific Precision Cancer Diagnostic Test Market Outlook
8.1 Asia-Pacific Market Analysis by Value (COVID-19 Impact Analysis)
8.2 Asia-Pacific Market Analysis by Country (COVID-19 Impact Analysis)
8.3 Japan Market Analysis
8.3.1 Japan Cancer Snapshot 2019
8.3.2 Japan Market Analysis by Value (COVID-19 Impact Analysis)
8.3.3 Cancer is the leading cause of death in Japan for more than 30 years
8.4 China Market Analysis
8.4.1 China Cancer Snapshot 2019
8.4.2 China Market Analysis by Value (COVID-19 Impact Analysis)
8.4.3 China is undergoing the cancer transition stage where the cancer spectrum is changing from developing country to developed country
8.5 India Market Analysis
8.5.1 India Cancer Snapshot 2019
8.5.2 India Market Analysis by Value (COVID-19 Impact Analysis)
8.5.3 Cancer is emerging as a major public health concern in India
8.6 Korea Market Analysis
8.6.1 Korea Cancer Snapshot 2019
8.6.2 Korea Market Analysis by Value (COVID-19 Impact Analysis)
8.6.3 In 2018, over 240,000 patients were newly diagnosed with cancer in Korea
8.7 Australia Market Analysis
8.7.1 Australia Cancer Snapshot 2019
8.7.2 Australia Market Analysis by Value (COVID-19 Impact Analysis)
8.7.3 Around 30 years ago, about 5 in 10 people survived for at least 5 years after their cancer diagnosis
8.8 Rest of Asia-Pacific Market Analysis by Value (COVID-19 Impact Analysis)
8.9 Asia-Pacific Market Analysis by Category (COVID-19 Impact Analysis)
8.10 Asia-Pacific Market Analysis by Cancer Imaging Testing Type (COVID-19 Impact Analysis)
8.11 Asia-Pacific Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
8.12 Asia-Pacific Market Analysis by End-User (COVID-19 Impact Analysis)

9 LAMEA Precision Cancer Diagnostic Test Market Outlook
9.1 LAMEA Market Analysis by Value (COVID-19 Impact Analysis)
9.2 LAMEA Market Analysis by Country (COVID-19 Impact Analysis)
9.3 Brazil Market Analysis
9.3.1 Brazil Cancer Snapshot 2019
9.3.2 Brazil Market Analysis by Value (COVID-19 Impact Analysis)
9.3.3 It is estimated that more than 600,000 new cases of cancer will be reported in Brazil
9.4 Saudi Arabia Market Analysis
9.4.1 Saudi Arabia Cancer Snapshot 2019
9.4.2 Saudi Arabia Market Analysis by Value (COVID-19 Impact Analysis)
9.4.3 The percentage of deaths due to cancer decreased after 70 years of age in Saudi Arabia population
9.5 South Africa Market Analysis
9.5.1 South Africa Cancer Snapshot 2019
9.5.2 South Africa Market Analysis by Value (COVID-19 Impact Analysis)
9.5.3 Lung cancer, cervical cancer, and oesophageal cancer are the three deadliest cancers in South Africa
9.6 Mexico Market Analysis
9.6.1 Mexico Cancer Snapshot 2019
9.6.2 Mexico Market Analysis by Value (COVID-19 Impact Analysis)
9.6.3 The main public health problems in the country are chronic degenerative diseases
9.7 UAE Market Analysis
9.7.1 UAE Cancer Snapshot 2019
9.7.2 UAE Market Analysis by Value (COVID-19 Impact Analysis)
9.7.3 The UAE is determined to bring down cancer fatalities by nearly 18 per cent by 2021
9.8 Rest of LAMEA Market Analysis by Value (COVID-19 Impact Analysis)
9.9 LAMEA Market Analysis by Category (COVID-19 Impact Analysis)
9.10 LAMEA Market Analysis by Cancer Imaging (COVID-19 Impact Analysis)
9.11 LAMEA Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
9.12 LAMEA Market Analysis by End-User (COVID-19 Impact Analysis)

10 Next Generation Cancer Diagnostics: Key Initiatives and Programs
10.1 Blood Profiling Atlas
10.1.1 Cancer-ID
10.1.2 Cancer Moon Shots
10.1.3 China Precision Medicine Initiative
10.1.4 ClinGen
10.2 CTC Trap Consortium
10.2.1 Early Cancer Detection Consortium
10.2.2 EpiFemCare
10.2.3 France Genomic Medicine Plan
10.2.4 Friends of Cancer Research Project
10.3 Human Cell Atlas
10.3.1 Immunomonitor Consortium
10.3.2 Integration of Imaging and Fluid-Based Tumour Monitoring
10.3.3 Liquid Biopsies and Imaging for Improved Cancer Care
10.3.4 Million Veteran Program
10.3.5 MedSeq
10.4 Next-Generation Single-Cell Analysis Program
10.4.1 Population Sequencing Projects
10.4.2 Precancer Atlas
10.4.3 Precision Medicine Initiative
10.4.4 Prompt
10.4.5 QuIP Project
10.5 Single-Cell Proteomics and Lipidomics Project
10.5.1 TopMed
10.5.2 Treehouse Childhood Cancer Initiative
10.5.3 Very Rare Cancer Consortium
10.6 Worldwide Innovative Networking (WIN) Consortium
10.6.1 Single-Cell Research
10.6.2 Cambridge Single-Cell Analysis Core Facility
10.6.3 Harvard Medical School Single-Cell Core
10.6.4 Mayo Medical Genome Facility
10.6.5 National Center for Single-Cell Biology
10.6.6 Single-Cell Analysis Core
10.6.7 UC San Francisco Single-Cell Analysis Center
10.6.8 Population Sequencing Programs

11 Leading Company Profiles
11.1 Abbott Laboratories Company
11.1.1 Company Information
11.1.2 Company Overview
11.1.3 Company Financial Profile
11.1.4 Company Product Offerings
11.1.5 Company Recent Developments
11.2 Agilent Technologies, Inc Company
11.2.1 Company Information
11.2.2 Company Overview
11.2.3 Company Financial Profile
11.2.4 Company Product Offerings
11.2.5 Company Recent Developments
11.3 Becton, Dickinson and Company
11.3.1 Company Information
11.3.2 Company Overview
11.3.3 Company Financial Profile
11.3.4 Company Product Offerings
11.3.5 Company Recent Developments
11.4 Bio-Rad Laboratories, Inc. Company
11.4.1 Company Information
11.4.2 Company Overview
11.4.3 Company Financial Profile
11.4.4 Company Product Offerings
11.4.5 Company Recent Developments
11.5 Canon Medical Systems Corporation Company
11.5.1 Company Information
11.5.2 Company Overview
11.5.3 Company Financial Profile
11.5.4 Company Product Offerings
11.5.5 Company Recent Developments
11.6 Biocept, Inc Company
11.6.1 Company Information
11.6.2 Company Overview
11.6.3 Company Financial Profile
11.6.4 Company Product Offerings
11.6.5 Company Recent Developments
11.7 Danaher Corporation Company
11.7.1 Company Information
11.7.2 Company Overview
11.7.3 Company Financial Profile
11.7.4 Company Product Offerings
11.7.5 Company Recent Developments
11.8 Roche Holding AG Company
11.8.1 Company Information
11.8.2 Company Overview
11.8.3 Company Financial Profile
11.8.4 Company Product Offerings
11.8.5 Company Recent Developments
11.9 Angle plc Company
11.9.1 Company Information
11.9.2 Company Overview
11.9.3 Company Financial Profile
11.9.4 Company Product Offerings
11.9.5 Company Recent Developments
11.10 Epigenomics AG Company
11.10.1 Company Information
11.10.2 Company Overview
11.10.3 Company Financial Profile
11.10.4 Company Product Offerings
11.10.5 Company Recent Developments
11.11 General Electric Company Company
11.11.1 Company Information
11.11.2 Company Overview
11.11.3 Company Financial Profile
11.11.4 Company Product Offerings
11.11.5 Company Recent Developments
11.12 Siemens AG Company
11.12.1 Company Information
11.12.2 Company Overview
11.12.3 Company Financial Profile
11.12.4 Company Product Offerings
11.12.5 Company Recent Developments
11.13 Biomerieux SA Company
11.13.1 Company Information
11.13.2 Company Overview
11.13.3 Company Financial Profile
11.13.4 Company Product Offerings
11.13.5 Company Recent Developments
11.14 Hologic, Inc Company
11.14.1 Company Information
11.14.2 Company Overview
11.14.3 Company Financial Profile
11.14.4 Company Product Offerings
11.14.5 Company Recent Developments
11.15 Myriad Genetics, Inc Company
11.15.1 Company Information
11.15.2 Company Overview
11.15.3 Company Financial Profile
11.15.4 Company Product Offerings
11.15.5 Company Recent Developments
11.16 Other Leading Companies in the Market

12 Conclusion & Recommendations
12.1 Recommendations for Clinicians
12.2 Recommendations for Policy Makers

13 Glossary

List of Figure
Figure 5.1 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 5.2 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 5.3 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 5.4 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 5.5 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.1 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.2 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.3 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.4 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.5 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.6 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.7 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.8 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.9 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.10 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.11 US Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 6.12 Canada Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 6.13 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.14 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.15 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.16 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.17 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.18 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.19 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.20 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.21 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.22 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.23 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.24 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.25 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.26 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.27 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.28 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.29 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.30 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.31 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.32 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.1 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.2 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.3 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.4 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.5 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.6 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.7 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.8 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.9 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.10 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.11 Russia Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 7.12 Germany Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 7.13 UK Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 7.14 France Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 7.15 Italy Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 7.16 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.17 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.18 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.19 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.20 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.21 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.22 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.23 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.24 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.25 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.26 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.27 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.28 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.29 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.30 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.31 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.32 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.33 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.34 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.35 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.1 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.2 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.3 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.4 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.5 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.6 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.7 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.8 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.9 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.10 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.11 Japan Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 8.12 China Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 8.13 India Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 8.14 Korea Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 8.15 Australia Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 8.16 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.17 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.18 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.19 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.20 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.21 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.22 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.23 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.24 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.25 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.26 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.27 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.28 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.29 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.30 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.31 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.32 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.33 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.34 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.35 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.1 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.2 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.3 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.4 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.5 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.6 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.7 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.8 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.9 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.10 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.11 Brazil Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 9.12 Saudi Arabia Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 9.13 South Africa Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 9.14 Mexico Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 9.15 UAE Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 9.16 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.17 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.18 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.19 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.20 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.21 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.22 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.23 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.24 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.25 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.26 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.27 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.28 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.29 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.30 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.31 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.32 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.33 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.34 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.35 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 11.1 Abbott Laboratories Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.2 Abbott Laboratories Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.3 Abbott Laboratories Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.4 Abbott Laboratories Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.5 Agilent Technologies, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.6 Agilent Technologies, Inc: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.7 Agilent Technologies, Inc: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.8 Agilent Technologies, Inc: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.9 Becton, Dickinson and Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.10 Becton, Dickinson and Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.11 Becton, Dickinson and Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.12 Becton, Dickinson and Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.13 Bio-Rad Laboratories, Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.14 Bio-Rad Laboratories, Inc. Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.15 Bio-Rad Laboratories, Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.16 Bio-Rad Laboratories, Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.17 Canon Medical Sys Corp Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.18 Canon Medical Sys Corp. Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.19 Canon Medical Sys Corp. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.20 Canon Medical Sys Corp. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.21 Biocept, Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.22 Biocept Inc. Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.23 Biocept Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.24 Biocept Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.25 Danaher Corporation Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.26 Danaher Corporation Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.27 Danaher Corporation Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.28 Danaher Corporation Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.29 Roche Holding AG. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.30 Roche Holding AG Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.31 Roche Holding AG. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.32 Roche Holding AG. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.33 Angle plc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.34 Angle plc Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.35 Angle plc. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.36 Angle plc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.37 Epigenomics AG. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.38 Epigenomics AG. Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.39 Epigenomics AG. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.40 Epigenomics AG. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.41 General Electric Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.42 General Electric Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.43 General Electric Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.44 General Electric Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.45 Siemens AG Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.46 Siemens AG Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.47 Siemens AG Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.48 Siemens AG Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.49 Biomérieux SA Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.50 Kkk. Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.51 Biomérieux SA Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.52 Biomérieux SA Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.53 Hologic, Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.54 Hologic, Inc Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.55 Hologic, Inc Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.56 Hologic, Inc Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.57 Myriad Genetics, Inc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.58 Myriad Genetics, Inc Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.59 Myriad Genetics, Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.60 Myriad Genetics, Inc Company: Company Net Income/Loss 2015-2019 (US$ Mn)

List of Tables
Table 2.1 Global Precision Cancer Diagnostic Test Market Summary Table
Table 3.1 Diagnostic Market Segments
Table 3.2 Next Generation Diagnostics: Key Analysis Platforms
Table 3.3 Analysis Platforms and Biomarker Types
Table 3.4 DNA Microarray Technologies in Cancer Diagnostics
Table 3.5 Design Features of Protein Microarray Technologies
Table 3.6 Microfluidic LOAC Types Used in Cancer Diagnostics
Table 3.7 Advanced Sequencing Technologies
Table 3.8 Illumina Next Generation Sequencing Workflow
Table 3.9 Thermo Fisher Scientific’s Next Generation Sequencing Workflow
Table 3.10 Main Ingredients of PCR Technology
Table 3.11 PCR Process
Table 3.12 Advantages of Droplet Digital PCR for Single-Cell Analysis
Table 3.13 Liquid Biopsy Biomarker Classes
Table 3.14 Cancer Genomic Sequencing and Liquid Biopsy
Table 3.15 Single-Cell Analysis to Identify Cancer Driver Mutations
Table 3.16 Genomics-Based Oncology Workflow
Table 3.17 Unique Challenges: CTC Capture and Analysis
Table 3.18 CTC Workflow
Table 3.19 Cell Differentiators
Table 3.20 Cell Isolation Technologies
Table 3.21 CTC Sample Preparation Technologies
Table 3.22 Single-Cell Analysis Technologies
Table 3.23 Estimated Annual Solid Biopsy Procedures, U.S., Selected Cancers
Table 3.24 Main Risks of Needle-Based Tissue Biopsies
Table 3.25 Factors in Tissue Biopsy
Table 3.26 Approaches to Avatar-Driven Cancer Diagnostics
Table 5.1 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.2 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.3 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.4 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.5 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 5.6 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.7 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.8 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.9 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.10 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 5.11 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.12 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.13 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.14 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.15 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 5.16 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.17 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.18 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.19 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.20 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 5.21 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.22 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.23 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.24 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.25 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 5.26 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.27 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.28 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.29 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.30 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.1 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.2 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.3 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.4 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.5 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.6 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.7 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.8 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.9 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.10 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.11 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.12 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.13 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.14 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.15 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.16 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.17 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.18 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.19 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.20 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.21 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.22 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.23 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.24 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.25 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.26 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.27 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.28 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.29 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.30 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.31 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.32 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.33 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.34 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.35 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.1 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.2 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.3 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.4 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.5 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.6 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.7 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.8 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.9 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.10 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.11 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.12 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.13 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.14 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.15 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.16 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.17 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.18 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.19 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.20 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.21 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.22 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.23 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.24 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.25 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.26 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.27 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.28 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.29 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.30 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.31 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.32 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.33 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.34 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.35 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.36 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.37 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.38 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.39 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.40 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.41 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.42 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.43 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.44 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.45 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.46 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.47 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.48 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.49 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.50 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.51 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.52 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.53 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.54 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.55 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.1 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.2 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.3 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.4 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.5 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.6 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.7 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.8 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.9 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.10 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.11 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.12 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.13 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.14 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.15 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.16 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.17 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.18 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.19 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.20 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.21 Korea Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.22 Korea Precision Cancer Dia

この商品のレポートナンバー

0000028539

TOP